Concepedia

Toxicity-driven Dose Adjustment

Toxicity-Driven Dose Adjustment is a dose modification strategy that systematically reduces or delays chemotherapy dosage in response to observed adverse effects, distinguishing itself from other strategies by prioritizing patient toxicity profiles as the primary criterion for altering treatment regimens.

26

Publications

1.2K

Citations

221

Authors

96

Institutions

Publications per year

2017–2026

5

Parents

Publications

26

Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?

Sophie Postel‐Vinay, Carlos Gomez‐Roca, L Rhoda Molife et al. · Journal of Clinical Oncology · 2011 · 138 citations

, , +16

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study

Sophie Postel‐Vinay, Laurence Collette, Xavier Paolettí et al. · European Journal of Cancer · 2014 · 122 citations

, , +17

Low-Dose Monitored Mitotane Treatment Achieves the Therapeutic Range with Manageable Side Effects in Patients with Adrenocortical Cancer<sup>1</sup>

Massimo Terzolo, Anna Pia, Alfredo Berruti et al. · The Journal of Clinical Endocrinology & Metabolism · 2000 · 116 citations · Full text

, , +15

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

R. Féty, F. Rolland, Muriel Barberi‐Heyob et al. · PubMed · 1998 · 114 citations

, , +17

Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.

PubMed · 2005 · 80 citations

, , +17

1–5 of 26

Authors

221

  1. JS
    Jean‐Charles Soria

    Institut Gustave Roussy, France

    2 publications · 260 citations

    2

    h-index

  2. SP
    Sophie Postel‐Vinay

    Institut Gustave Roussy, France

    2 publications · 260 citations

    2

    h-index

  3. SB
    Stan B. Kaye

    Royal Marsden NHS Foundation Trust, United Kingdom

    2 publications · 260 citations

    2

    h-index

  4. XP
    Xavier Paolettí

    Inserm, France

    2 publications · 260 citations

    2

    h-index

  5. AA
    Antoine Adenis

    Centre Oscar Lambret, France

    1 publications · 38 citations

    1

    h-index

1–5 of 221

Institutions

96

  1. Institut Curie

    Paris, France

    2 h-index

    12 publications

    1.6K citations

  2. Inserm

    Paris, France

    2 h-index

    12 publications

    1.6K citations

  3. Emory University

    Atlanta, United States

    2 h-index

    8 publications

    102 citations

  4. University of Warwick

    Coventry, United Kingdom

    2 h-index

    2 publications

    67 citations

  5. Princess Margaret Cancer Centre

    Toronto, Canada

    2 h-index

    4 publications

    206 citations

  6. Institut Gustave Roussy

    Villejuif, France

    2 h-index

    13 publications

    1.7K citations

  7. Royal Marsden Hospital

    London, United Kingdom

    2 h-index

    11 publications

    1.5K citations

  8. BC Cancer Agency

    Vancouver, Canada

    2 h-index

    13 publications

    771 citations

1–8 of 96

Venues

  1. Journal of Gastrointestinal Cancer

    2 publications · 22 citations

    2

    h-index

  2. European Journal of Cancer

    2 publications · 150 citations

    2

    h-index

  3. PubMed

    Repository · 2 publications · 194 citations

    2

    h-index

  4. Cancer Chemotherapy and Pharmacology

    2 publications · 134 citations

    2

    h-index

  5. Journal of Clinical Oncology

    2 publications · 206 citations

    2

    h-index

1–5